Top 2 Health Care Stocks That May Crash This Month
Private Equity Firms Who Hold 38% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Gained 32%, Institutions Profited as Well
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Analysts' Opinions Are Mixed on These Healthcare Stocks: HilleVax, Inc (HLVX), Lexicon Pharmaceuticals (LXRX) and Arvinas Holding Company (ARVN)
Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline
Novo Nordisk Gains Exclusive Rights to Lexicon's Non-incretin Obesity Drug Candidate
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
Trending Stocks Today | Portage Biotech Shoots up 98.51%
Top Midday Gainers
Express News | HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target
Lexicon Pharmaceuticals Analyst Ratings
Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating
The weight loss drug newcomer Lesacon (LXRX.US) has secured a L from Novo-Nordisk A/S (NVO.US), with potential earnings reaching up to 1 billion.
Lexicon Pharmaceuticals announced an exclusive licensing agreement with Novo-Nordisk A/S to collaboratively develop its obesity candidate drug LX9851.
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected
Wall Street Set to Open Lower Friday as Inflation Rises More Than Expected
Sector Update: Health Care Stocks Steady Premarket Friday
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
12 Health Care Stocks Moving In Friday's Pre-Market Session
Express News | Lexicon Pharmaceuticals Inc - Entitled to Tiered Royalties on Net Sales of Lx9851
Express News | Lexicon Pharmaceuticals Inc - Eligible for up to $75 Million in Upfront and Near-Term Milestone Payments